Welcome to our dedicated page for Royalty Pharma news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma stock.
Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $250 million to Zymeworks (Nasdaq: ZYME) via a non‑recourse royalty‑backed note secured by 30% of worldwide tiered royalties on Ziihera until repayment.
Repayment ends when Royalty Pharma receives 1.65x the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% royalties and all milestone payments up to $1.5 billion potential remaining. Proceeds fund share repurchases, potential acquisitions, and cash runway beyond 2028.
Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. According to the company, the session will be webcast and archived for at least thirty days.
Investors can access the live webcast and archived replay via the company’s Events page.
Royalty Pharma (Nasdaq: RPRX) reported Q4 2025 Portfolio Receipts of $874 million and full‑year 2025 Portfolio Receipts of $3,254 million, growth of 18% Q4 and 16% FY. Net cash provided by operations was $827 million in Q4 and $2,490 million for FY 2025.
The company deployed $2.6 billion on royalty transactions in 2025, repurchased 37 million Class A shares for $1.2 billion, and raised the quarterly dividend 7% to $0.235 per share. Full‑year 2026 Portfolio Receipts guidance is $3,275M–$3,425M.
Royalty Pharma (Nasdaq: RPRX) will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Investors can obtain conference call details and view the live webcast via the company's Investors page, and a replay will be archived on the site for at least 30 days.
Royalty Pharma (Nasdaq: RPRX) provided a business update and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Key highlights: the announced royalty funding market reached a record $10 billion in 2025; Royalty Pharma announced $4.7 billion of transactions in 2025 (capital deployment of $2.6 billion), representing ~40% market share. The company expects to meet 2025 Portfolio Receipts guidance of $3,200–$3,250 million (14%–16% growth) and reported trailing twelve‑month ROIC 15.7% and ROIE 22.9%. Multiple 2026 milestones are anticipated, including pivotal readouts for daraxonrasib, litifilimab and pelacarsen, and several potential approvals; late‑stage pipeline peak sales potential exceeds $43 billion, which could translate to >$2.1 billion annually in new royalties.
Royalty Pharma (Nasdaq: RPRX) agreed to provide up to $500 million to accelerate Teva's anti‑IL‑15 antibody, TEV‑'408, including $75 million of R&D co‑funding to support a Phase 2b vitiligo study targeted to start in 2026 and a Royalty Pharma option to provide an additional $425 million to co‑fund a Phase 3 program. TEV‑'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, and Teva expects to share trial results during 2026.
If approved and launched, Teva will pay a milestone to Royalty Pharma and a royalty on worldwide net sales of TEV‑'408.
Royalty Pharma (Nasdaq: RPRX) announced a first-quarter 2026 dividend of $0.235 per Class A ordinary share, representing a 6.8% increase versus the prior quarter. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026.
Royalty Pharma (Nasdaq: RPRX) acquired the remaining portion of PTC Therapeutics’ royalty on Roche’s Evrysdi for $240 million upfront plus up to $60 million in sales‑based milestones. Following the deal, Royalty Pharma will own 100% of a tiered 8%–16% royalty on worldwide net sales of Evrysdi.
Evrysdi is an oral SMN2 splicing modifier for spinal muscular atrophy, FDA approved in 2020 and used by >21,000 patients. Evrysdi reported CHF 1.6 billion (~$1.9B) sales in 2024, +18% year‑over‑year at constant FX, and analyst consensus projects CHF 2.3 billion (~$2.9B) by 2030. The increased royalty structure applies starting Q1 2026, based on Q4 2025 product sales.
Royalty Pharma (Nasdaq: RPRX) acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from a third party for up to $315 million.
Both are next-generation TKIs for ALK and ROS1 mutation-positive NSCLC. Neladalkib reported positive pivotal results in November 2025 and is in a Phase 3 study in TKI-naïve patients. Zidesamtinib is under U.S. FDA review with an action date of September 18, 2026 and is in Phase 1/2 for TKI-naïve patients.
Royalty Pharma acquired a low-single-digit royalty on worldwide net sales, with expected royalty duration through approximately 2041–2042. Existing analyst consensus projects peak sales of about $3.5B for neladalkib and $1.9B for zidesamtinib by 2035.
Royalty Pharma (Nasdaq: RPRX) agreed to provide $275 million in synthetic royalty funding to Denali Therapeutics (Nasdaq: DNLI) tied to future net sales of tividenofusp alfa for MPS II (Hunter syndrome).
Royalty Pharma will pay $200 million at closing and an additional $75 million upon EMA approval by Dec 31, 2029. In return, Royalty Pharma receives a 9.25% royalty on worldwide net sales, capped at a 3.0x multiple (or 2.5x if reached by Q1 2039). The transaction requires U.S. FDA accelerated approval (PDUFA date Apr 5, 2026).